Bryan Ball, who serves as Chief Technical Operations Officer and Senior Vice President of Manufacturing Operations at Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), completed two stock sales on April 9 and April 10, 2026, that together total 56,596 shares of common stock.
The first transaction, executed on April 9, involved the disposition of 50,000 shares at a price of $3.57 per share. The second transaction, on April 10, consisted of an additional 6,596 shares sold at $3.43 per share. Both trades were broker-assisted and produced combined gross proceeds of $201,124.
Following these sales, Ball holds a direct stake of 515,955 shares of Whitehawk Therapeutics common stock. Company filings indicate the transactions were carried out specifically to satisfy tax withholding obligations tied to the vesting of restricted stock units.
The stock has recorded notable market appreciation recently: the share price has risen more than 103% over the past year and roughly 76% across the prior six months.
Analyst coverage and platform commentary
According to analysis from InvestingPro cited in company commentary, WHWK appears undervalued at current levels. The InvestingPro platform highlights Whitehawk’s strong one-year return among a set of additional insights labeled as ProTips available to subscribers. The platform also notes that WHWK’s Pro Research Report is one of more than 1,400 comprehensive research reports that InvestingPro offers for U.S. equities.
Scientific update presented at SGO 2026
In separate company news, Whitehawk Therapeutics presented data at the Society of Gynecologic Oncology 2026 Annual Meeting examining expression patterns of the protein MUC16 in ovarian and endometrial cancers. The analysis, completed in collaboration with Tempus AI, found that MUC16 expression in ovarian cancer is substantially higher than for other antibody-drug conjugate (ADC) targets referenced in the presentation.
The reported expression differentials ranged from roughly 2-fold to more than 100-fold higher than targets such as NaPi2b and HER2, among others. Presentation material also indicated that MUC16 protein expression remained stable across disease stages, metastatic status and platinum sensitivity within high-grade serous ovarian carcinoma, a subtype that accounts for about 70% of ovarian cancer cases.
The company characterized these findings as providing important insights into potential therapeutic targets for ovarian cancer treatment.
What is and is not in the record
The publicly disclosed details on the insider transactions specify the shares sold, prices, dates and the stated reason for the broker-assisted sales. The public commentary also records InvestingPro’s valuation view and summarizes the MUC16 expression data presented at SGO 2026. The disclosures do not include additional information on any subsequent changes in executive ownership intentions, nor do they report clinical outcomes tied to the presented expression data.